AUPH — Aurinia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.84bn
- $283.06m
U.S. STOCKS ON THE MOVE-Super Micro, Albemarle
U.S. STOCKS ON THE MOVE-Ginkgo, Jfrog, Alvotech
Aurinia Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
U.S. STOCKS ON THE MOVE-EPAM, CBRE, Zebra Technologies
U.S. STOCKS ON THE MOVE-premarket
Aurinia Pharma declines as company fails to find buyer
Aurinia to stop development of immunotherapies after strategic review (updated)
Aurinia to stop R&D on immunotherapies to focus on kidney disease drug
Brief: Aurinia Pharmaceuticals Q4 EPS USD -0.19
Kidney drug developer Aurinia fails to clinch a sale, sources say
Aurinia Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Aurinia Submits IND Application to US FDA for AUR 200
Brief: Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) For Lupkynis® (Voclosporin) In Japan
Aurinia Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Aurinia Pharmaceuticals Q3 EPS USD -0.09
Aurinia Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Aurinia Board Of Directors Appoints Dr. Robert T. Foster As New Board Director
Brief: Aurinia Appoints Two New Board Directors With Experience In Biopharma Leadership, Commercial Strategy, M&A And Advancing Therapeutic Pipelines
Aurinia Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary